Annotation Detail

Information
Associated Genes
CCND1
Associated Variants
CCND1 AMPLIFICATION ( ENST00000227507.3 )
CCND1 AMPLIFICATION ( ENST00000227507.3 )
Associated Disease
ovarian cancer
Source Database
CIViC Evidence
Description
A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proliferation. Large variation in palbociclib sensitivity was observed and cell lines (N=40) were classified as above (resistant) or below (sensitive) the mean log of all IC50 values. 6/18 (33%) of the resistant lines and in only 1/22 (5%) of the sensitive lines (P = 0.017) had CCND1 copy number gain. Increased CCND1 expression was not correlated with sensitivity to palbociclib (p=0.671).
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1599
Gene URL
https://civic.genome.wustl.edu/links/genes/8
Variant URL
https://civic.genome.wustl.edu/links/variants/18
Rating
3
Evidence Type
Predictive
Disease
Ovarian Cancer
Evidence Direction
Does Not Support
Drug
Palbociclib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
21278246
Drugs
Drug NameSensitivitySupported
PalbociclibSensitivityfalse